Clinical Trial Update: Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a combination therapy of Wharton’s Jelly-derived mesenchymal stem cells and Magnovision for retinitis pigmentosa has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• Magnovision
• Wharton's Jelly Derived Mesenchymal Stem Cells (mesenchymal stem cells)

Snippet

Sponsor: Ankara Universitesi Teknokent | Conditions: Retinitis Pigmentosa | Phase 3 | Status: COMPLETED